24 Hours Treatment with Alteplase in Patients with Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.

Also called NCT04879615

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 372 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04879615
Other papers using this trial's data
  • Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial JAMA, 2025-09-02 DOI, PubMed 40773205, PMC12332759 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04879615. Randomized; single masking; primary purpose treatment. Start 2021-06-21 (actual); primary completion 2024-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
Condition
Stroke
Intervention (Drug)
Alteplase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct04879615
Content hash
266e28eda1c825f1e2a8cc3bf91e4d9ab993da4d97ed8190737c925fd512fc2d